Activating two somatostatin receptors enhances amyloid beta breakdown and improves memory in models of Alzheimer’s disease. Scientists at Karolinska Institutet in Sweden and the RIKEN Center for Brain ...

"These results are stunning." The post Scientists Identify Possible Game Changing Treatment for Alzheimer’s Disease That ...

An experimental drug called NU-9 has shown promise as an early intervention for Alzheimer's disease. | Drug Discovery And ...

An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for ...

In a joint study by researchers at the University of Rochester, US, and Indian researchers found that immune cells in the ...

According to a recent study, even light walking of about 5,000 steps per day can delay the rate of cognitive decline caused ...

A new drug targets Alzheimer’s at its earliest, most silent stage — before memory loss ever begins. Credit: Shutterstock. A ...

Explore the potential of experimental drug NU-9 in early Alzheimer's intervention, targeting toxic amyloid beta forms.

Northwestern University scientists are developing an experimental drug that could serve as an early intervention for Alzheimer’s disease.

The drug is called NU-9, and a team from Northwestern University in the US tested it on mouse models of Alzheimer's disease.

A study highlights that immune cells in female brains may activate genes tied to neuroinflammation more than in males, shedding light on why women are more frequently diagnosed with Alzheimer's ...

New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...